ODAC Calls For Tougher Standards For Accelerated Approval In Oncology
Sponsors Withdraw Indications for Iressa, Celebrex
Doroshow: NCI Leaves It Up to Groups To Make Their Own Merger Deals
White House Yet To Name NCAB, Cancer Panel Members
NCI Largely Unaffected By NIH Translational Research Center
Trending Stories
- Karen Knudsen to leave ACS
- A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies - Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Tumors are able to form with no DNA mutations, fly study shows
- From clinician scientist to nonprofit CEO